HIV PrEP + STI PEP for HIV Prevention
What You Need to Know Before You Apply
What is the purpose of this trial?
Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men
Who Is on the Research Team?
Jorge Gallardo-Cartagena, MD
Principal Investigator
Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales
Susan Buchbinder, MD
Principal Investigator
San Francisco Department of Public Health and University of California San Francisco
Thiago Torres, MD
Principal Investigator
Instituto Nacional de Infectología Evandro Chagas
Are You a Good Fit for This Trial?
This trial is for young men at risk of HIV or sexually transmitted infections (STIs). Participants should not already have HIV, certain cancers like Non-Hodgkin's Lymphoma, or hepatitis B. The study is focused on those who could benefit from preventive treatments.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- 3P mHealth package
- CAB-LA
- Doxycycline as Doxy-PEP
- F/TAF
- F/TDF
- Handout about HIV PrEP options available at the site
- Standard-of-care HIV PrEP counseling from qualified study staff
Trial Overview
The trial compares different ways to prevent HIV and STIs: daily or long-acting PrEP medications (F/TDF, F/TAF, CAB-LA), STI prevention with doxycycline after sex (Doxy-PEP), a mobile health support package, educational handouts about PrEP options, and standard counseling.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
HIV PrEP, doxy-PEP, 3P mHealth package (3P: MyPrEP + PrEPmate + PrEPsmart tools) to assist with PrEP uptake and adherence decision making, standard-of-care PrEP adherence counseling from qualified study staff, handout about the different PrEP options available at the site
HIV PrEP, doxy-PEP, standard-of-care PrEP adherence counseling from qualified study staff, handout about the different PrEP options available at the site
Find a Clinic Near You
Who Is Running the Clinical Trial?
HIV Prevention Trials Network
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Gilead Sciences
Industry Sponsor
Daniel O'Day
Gilead Sciences
Chief Executive Officer since 2019
MBA from Columbia University
Dietmar Berger
Gilead Sciences
Chief Medical Officer
MD and PhD from Albert-Ludwigs University School of Medicine
ViiV Healthcare
Industry Sponsor
Dr. Harmony Garges
ViiV Healthcare
Chief Medical Officer
MD
Deborah Waterhouse
ViiV Healthcare
Chief Executive Officer since 2017
Bachelor's degree in Business Administration
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.